Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Kestra Private Wealth Services LLC

Kestra Private Wealth Services LLC grew its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 14.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,012 shares of the medical research company’s stock after purchasing an additional 1,288 shares during the period. Kestra Private Wealth Services LLC’s holdings in Thermo Fisher Scientific were worth $5,314,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of TMO. Accurate Wealth Management LLC boosted its stake in shares of Thermo Fisher Scientific by 6.3% during the 3rd quarter. Accurate Wealth Management LLC now owns 553 shares of the medical research company’s stock worth $268,000 after purchasing an additional 33 shares during the last quarter. Vicus Capital acquired a new stake in shares of Thermo Fisher Scientific in the third quarter worth approximately $344,000. Cambridge Investment Research Advisors Inc. boosted its position in shares of Thermo Fisher Scientific by 16.3% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 43,128 shares of the medical research company’s stock worth $21,830,000 after acquiring an additional 6,055 shares during the last quarter. Kingswood Wealth Advisors LLC boosted its position in shares of Thermo Fisher Scientific by 14.2% in the third quarter. Kingswood Wealth Advisors LLC now owns 995 shares of the medical research company’s stock worth $504,000 after acquiring an additional 124 shares during the last quarter. Finally, Mission Wealth Management LP boosted its position in shares of Thermo Fisher Scientific by 32.8% in the third quarter. Mission Wealth Management LP now owns 4,156 shares of the medical research company’s stock worth $2,104,000 after acquiring an additional 1,026 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the transaction, the senior vice president now owns 12,901 shares of the company’s stock, valued at $7,250,362. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the transaction, the senior vice president now owns 12,901 shares of the company’s stock, valued at $7,250,362. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The disclosure for this sale can be found here. Insiders sold a total of 52,277 shares of company stock valued at $29,649,264 over the last 90 days. 0.34% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on TMO. Citigroup began coverage on shares of Thermo Fisher Scientific in a research report on Monday, March 18th. They issued a “neutral” rating and a $620.00 target price on the stock. Barclays raised their price target on shares of Thermo Fisher Scientific from $590.00 to $615.00 and gave the company an “equal weight” rating in a report on Thursday, April 25th. Royal Bank of Canada raised their price target on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a report on Thursday, February 1st. Robert W. Baird cut their price target on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a report on Thursday, April 25th. Finally, HSBC raised their price target on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a report on Tuesday. Five investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $607.35.

Thermo Fisher Scientific Stock Down 1.4 %

Shares of NYSE:TMO opened at $568.74 on Wednesday. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68. The company has a fifty day simple moving average of $574.58 and a 200 day simple moving average of $531.67. The firm has a market cap of $217.09 billion, a PE ratio of 36.48, a price-to-earnings-growth ratio of 2.40 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.70 by $0.41. The business had revenue of $10.35 billion during the quarter, compared to analyst estimates of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.59 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date was Thursday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s payout ratio is currently 10.01%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.